NO20063599L - Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister - Google Patents
Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonisterInfo
- Publication number
- NO20063599L NO20063599L NO20063599A NO20063599A NO20063599L NO 20063599 L NO20063599 L NO 20063599L NO 20063599 A NO20063599 A NO 20063599A NO 20063599 A NO20063599 A NO 20063599A NO 20063599 L NO20063599 L NO 20063599L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- heterocyclic compounds
- glutamate receptor
- further heterocyclic
- metabotrophic glutamate
- Prior art date
Links
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60896004P | 2004-02-18 | 2004-02-18 | |
PCT/US2005/004774 WO2006014185A1 (en) | 2004-02-18 | 2005-02-15 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063599L true NO20063599L (no) | 2006-10-27 |
Family
ID=35447957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063599A NO20063599L (no) | 2004-02-18 | 2006-08-08 | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister |
Country Status (27)
Country | Link |
---|---|
US (6) | US7585881B2 (de) |
EP (2) | EP1723144B1 (de) |
JP (1) | JP4912157B2 (de) |
CN (2) | CN1984907A (de) |
AT (1) | ATE483706T1 (de) |
AU (1) | AU2005270208A1 (de) |
BR (1) | BRPI0507497A (de) |
CA (1) | CA2555566A1 (de) |
CY (1) | CY1110965T1 (de) |
DE (1) | DE602005023963D1 (de) |
DK (1) | DK1723144T3 (de) |
ES (1) | ES2352110T3 (de) |
HK (1) | HK1099285A1 (de) |
HR (1) | HRP20100654T1 (de) |
IL (1) | IL177394A0 (de) |
NO (1) | NO20063599L (de) |
NZ (1) | NZ548954A (de) |
PL (1) | PL1723144T3 (de) |
PT (1) | PT1723144E (de) |
RS (1) | RS51516B (de) |
RU (1) | RU2370495C2 (de) |
SG (1) | SG146657A1 (de) |
SI (1) | SI1723144T1 (de) |
UA (1) | UA84318C2 (de) |
UY (1) | UY28766A1 (de) |
WO (1) | WO2006014185A1 (de) |
ZA (1) | ZA200606551B (de) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723941A (zh) * | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑 |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1740559B1 (de) * | 2004-04-20 | 2014-10-15 | Merck Sharp & Dohme Corp. | Als beta-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete 1,3,5-substituierte phenylderivatverbindungen |
WO2006080533A1 (ja) * | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | 3-アミノ-1,2,4-トリアゾール誘導体 |
UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
CA2657247A1 (en) * | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
EP2167464B1 (de) * | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Heterocyclische verbindungen als positive modulatoren des metabotropen glutamatrezeptors 2 (mglu2-rezeptor) |
CA2696016A1 (en) * | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
KR20100090777A (ko) * | 2007-10-19 | 2010-08-17 | 아스트라제네카 아베 | 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체 |
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
CA2704684A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
EP2255009A4 (de) * | 2008-03-03 | 2011-08-10 | Stiefel Laboratories | Verfahren zur herstellung von enantiomerenreinen diol- und dioxolanverbindungen |
EP3782991A1 (de) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Neue modulatoren von sphingosinphophatrezeptoren |
CA2730037A1 (en) * | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
KR20110040910A (ko) * | 2008-08-12 | 2011-04-20 | 아스트라제네카 아베 | 4-(5-((1r)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4h-1,2,4-트리아졸-3-일)피리딘의 결정질 형태 |
RU2011103225A (ru) * | 2008-08-12 | 2012-09-20 | Астразенека Аб (Se) | Новая кристаллическая форма 4-(5-{(1r)-1-[5-(3-хрорфенил)изоксазол-3-ил]этокси}-4-метил-4h-1,2,4-триазол-3-ил)пиридина |
PE20110397A1 (es) * | 2008-09-25 | 2011-07-01 | Boehringer Ingelheim Int | Compuestos que modulan selectivamente el receptor cb2 |
CN102256967A (zh) * | 2008-12-18 | 2011-11-23 | 阿斯利康(瑞典)有限公司 | 制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法 |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する複素環化合物 |
JP5651681B2 (ja) * | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 |
US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
WO2010139966A1 (en) * | 2009-06-05 | 2010-12-09 | Oslo University Hospital Hf | Azole derivatives as wtn pathway inhibitors |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
JP2013505295A (ja) * | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節する化合物 |
US8357706B2 (en) * | 2009-11-13 | 2013-01-22 | Receptos, Inc. | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
KR101771755B1 (ko) * | 2009-11-13 | 2017-08-25 | 셀진 인터내셔널 Ii 에스에이알엘 | 선택적 헤테로시클릭 스핑고신 1 포스페이트 수용체 조절자 |
MY189750A (en) * | 2009-11-13 | 2022-03-02 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
CA2784768C (en) * | 2009-12-29 | 2015-02-03 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
CN101712641B (zh) * | 2009-12-29 | 2013-05-08 | 江苏工业学院 | 一种甲硫基苯甲酸的制备方法 |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
EP2531510B1 (de) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo-[5,1b-]oxazol-derivate als crf-1-rezeptor-antagonisten |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するテトラゾール化合物 |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
WO2012058128A2 (en) * | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
EP2649063A1 (de) | 2010-12-08 | 2013-10-16 | Oslo University Hospital HF | Triazolderivate als wnt-signalpfadinhibitoren |
DE102010063974B4 (de) * | 2010-12-22 | 2021-10-07 | Thomas Rühl | Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung |
EP2685977A1 (de) | 2011-03-18 | 2014-01-22 | Novartis AG | Kombinationen von nikotinischen acetylcholinrezeptor-alpha-7-aktivatoren und mglur5-antagonisten zur verwendung in einer dopamininduzierten dyskinesie bei morbus parkinson |
US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
JP6129159B2 (ja) | 2011-05-13 | 2017-05-17 | レセプトス エルエルシー | 選択的複素環式スフィンゴシン1−リン酸受容体モジュレーター |
EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
EP2803668A1 (de) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole |
HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
EP3265446B1 (de) * | 2015-03-05 | 2019-08-14 | Bayer CropScience Aktiengesellschaft | Verfahren zur herstellung von substituierten phenylisoxazolin-derivate |
EP4023645A1 (de) | 2015-03-10 | 2022-07-06 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazol- und thiadiazol-verbindungen als immunmodulatoren |
SG11201706902SA (en) * | 2015-03-10 | 2017-09-28 | Aurigene Discovery Tech Ltd | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
WO2017218337A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
EA202090536A1 (ru) | 2017-10-11 | 2020-07-22 | Ориджен Дискавери Текнолоджис Лимитед | Кристаллические формы 3-замещенного 1,2,4-оксадиазола |
EA202090746A1 (ru) | 2017-11-03 | 2020-08-17 | Ориджен Дискавери Текнолоджис Лимитед | Двойные ингибиторы путей tim-3 и pd-1 |
AU2018360389A1 (en) | 2017-11-06 | 2020-05-07 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
CA3075664C (en) * | 2017-11-16 | 2020-12-29 | Montdorex Inc. | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity |
ES2945834T3 (es) | 2018-10-05 | 2023-07-07 | Forma Therapeutics Inc | Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30) |
SG11202107434PA (en) | 2019-01-15 | 2021-08-30 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
EP3927683A1 (de) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Feste formen von fxr-agonisten |
PE20220016A1 (es) * | 2019-05-03 | 2022-01-11 | Praxis Prec Medicines Inc | Inhibidores y metodos de uso de kcnt1 |
PE20230165A1 (es) * | 2020-01-07 | 2023-02-01 | Disarm Therapeutics Inc | Inhibidores de sarm1 |
WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4538833A (en) * | 1983-12-08 | 1985-09-03 | P I E International Inc. | Publication |
US5403138A (en) * | 1991-10-09 | 1995-04-04 | Fuji Photo Film Co., Ltd. | Booklet album including a double-sided photograph and a method of making the same |
US5332265A (en) * | 1993-01-22 | 1994-07-26 | Minnesota Mining And Manufacturing Company | Advertising assembly |
AU780191B2 (en) | 1999-08-19 | 2005-03-03 | Astrazeneca Ab | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU2002360621B2 (en) | 2001-12-19 | 2007-01-25 | Merck & Co., Inc. | heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
CN101723941A (zh) * | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑 |
MXPA05001590A (es) * | 2002-08-09 | 2005-05-23 | Astrazeneca Ab | Compuestos que tienen actividad en los receptores metabotropicos de glutamato. |
EP1536790A2 (de) | 2002-08-09 | 2005-06-08 | AstraZeneca AB | Oxadiazole als modulatoren des metabotropischen glutamatrezeptors-5 |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
-
2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/en unknown
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es active Active
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 EP EP05802855A patent/EP1723144B1/de active Active
- 2005-02-15 EP EP10182161A patent/EP2311830A1/de not_active Withdrawn
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de active Active
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 CA CA002555566A patent/CA2555566A1/en not_active Abandoned
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/en active Application Filing
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
-
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
-
2007
- 2007-05-22 HK HK07105399.9A patent/HK1099285A1/xx not_active IP Right Cessation
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
-
2010
- 2010-11-29 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
NO20062677L (no) | Benzyleteraminforbindelser anvendbare som CCR-5-antagonister | |
DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
NO20070336L (no) | Indolderivater som histamin-reseptorantagonister | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
NO20073663L (no) | Tiazol-4-karboksamid-derivater som mGluR5 antagonister | |
NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
NO20076479L (no) | Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer | |
NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. | |
NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
GEP20094727B (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
NO20070555L (no) | Kinazolinonderivater som parp-inhibitorer | |
NO20084489L (no) | Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet | |
NO20075406L (no) | Pyrimidindionerivater som prokineticin-2-reseprorantagonister | |
NO20055219L (no) | Nye forbindelser | |
ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
NO20076478L (no) | Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |